INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 285 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,604,715 | -23.4% | 50,750 | -1.3% | 0.51% | -19.2% |
| Q2 2023 | $2,096,092 | +21.6% | 51,400 | +11.1% | 0.63% | +15.6% |
| Q1 2023 | $1,724,297 | +8.2% | 46,265 | +1.3% | 0.54% | -2.0% |
| Q4 2022 | $1,593,252 | -32.1% | 45,665 | +8.8% | 0.56% | -33.5% |
| Q3 2022 | $2,348,000 | +5.0% | 41,965 | -2.9% | 0.84% | +8.6% |
| Q2 2022 | $2,237,000 | -30.7% | 43,225 | -2.8% | 0.77% | -20.2% |
| Q1 2022 | $3,230,000 | -42.5% | 44,450 | -6.5% | 0.96% | -32.7% |
| Q4 2021 | $5,619,000 | -17.8% | 47,525 | -6.7% | 1.43% | -13.4% |
| Q3 2021 | $6,835,000 | -13.2% | 50,950 | +4.7% | 1.65% | -6.9% |
| Q2 2021 | $7,877,000 | +71.0% | 48,650 | -32.1% | 1.78% | +40.4% |
| Q1 2021 | $4,606,000 | +28.4% | 71,625 | +8.6% | 1.26% | +17.9% |
| Q4 2020 | $3,586,000 | +294.9% | 65,925 | +44.4% | 1.07% | +212.8% |
| Q3 2020 | $908,000 | – | 45,650 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 744,160 | $54,078,000 | 5.79% |
| Discovery Value Fund | 986,173 | $71,665,000 | 5.28% |
| Ally Bridge Group (NY) LLC | 60,000 | $4,360,000 | 3.23% |
| MPM BioImpact LLC | 159,409 | $11,584,000 | 3.11% |
| ARK Investment Management | 8,981,029 | $652,651,000 | 2.72% |
| Elmwood Wealth Management, Inc. | 67,599 | $4,912,000 | 2.52% |
| Nikko Asset Management Americas, Inc. | 2,872,269 | $192,442,000 | 1.41% |
| Frazier Life Sciences Management, L.P. | 203,684 | $14,802,000 | 1.26% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $8,098,000 | 1.22% |
| Merlin Capital, Inc | 11,575 | $841,000 | 1.11% |